ArticleCancer management and research2026
High Expression of BTN3A3 Acts as an Independent Predictive Factor of Better Prognosis in Patients with Sarcomas.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Butyrophilin subfamily 3 member A3 (BTN3A3) may be used as a prognostic biomarker for various malignancies. However, there is little evidence on the role of BTN3A3 in sarcomas. Methods: Using data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), we detected BTN3A3 in normal and sarcomas tissues. Then we further evaluated clinical relevance, prognostic significance, genetic alternations, DNA methylation, co-expression gene and correlations with immune infiltration of BTN3A3. Results: The results showed that BTN3A3 expression was higher in sarcoma tissues than in normal tissues. The expression of BTN3A3 was regulated by methylation and miRNA. Higher BTN3A3 expression was associated with a better prognosis of sarcomas than lower BTN3A3 expression. GSEA revealed that the JAK-STAT signaling pathway, cytokine-cytokine receptor interaction, NK cell-mediated cytotoxicity, T cell receptor signaling pathway, cell adhesion, and Toll-like receptor signaling were differentially enriched in patients with elevated BTN3A3 expression. The BTN3A3 expression were found to be positively correlated with immune infiltration, immune checkpoints. In the multivariate analysis, high BTN3A3 expression was found to be an independent risk factor for overall survival. Conclusion: In conclusion, increased BTN3A3 expression is a significant predictor of better prognosis in patients with sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.